A Phase 1 Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies.
Phase of Trial: Phase I
Latest Information Update: 12 Jul 2016
At a glance
- Drugs ENMD 2076 (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors CASI Pharmaceuticals; EntreMed
- 12 Jul 2016 Results published in the Investigational New Drugs
- 03 Aug 2011 Actual end date (1 May 2011) added as reported by ClinicalTrials.gov.
- 03 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.